Welcome to our dedicated page for Fonar SEC filings (Ticker: FONR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fonar Corporation revolutionized diagnostic imaging with the first upright MRI, and its SEC filings continue to reveal how that innovation translates into revenue from both scanner sales and a nationwide network of imaging centers. Each document holds clues about scan volumes, reimbursement trends, and service contracts that drive cash flow—information too important to leave buried in footnotes.
Need the latest Fonar quarterly earnings report 10-Q filing or want to review Fonar insider trading Form 4 transactions? Stock Titan delivers Fonar SEC filings explained simply. Our AI reads every page, highlights segment margins, flags FDA-related disclosures from 8-Ks, and converts technical language into clear takeaways. You’ll understand scan-volume growth without wading through medical jargon.
Real-time alerts mean Fonar Form 4 insider transactions real-time hit your dashboard seconds after EDGAR posts. From a Fonar annual report 10-K simplified to a concise Fonar proxy statement executive compensation summary, every filing arrives fully annotated. Even market-moving notices get the Fonar 8-K material events explained treatment, complete with context and historical comparisons.
- AI-powered summaries surface reimbursement and scan-volume insights
- Instant alerts for Fonar executive stock transactions Form 4
- Side-by-side Fonar earnings report filing analysis across quarters
- Searchable archive for understanding Fonar SEC documents with AI
Spend less time parsing filings and more time modeling how Fonar’s breakthrough MRI technology drives long-term value.
Fonar Corporation (Nasdaq: FONR) filed a Form 8-K on June 23, 2025 to disclose a governance change under Item 5.02. Claudette J.V. Chan, a member of the Board of Directors and the Company’s Secretary, notified the Company of her intention to retire effective June 19, 2025. The filing explicitly states that Ms. Chan cited no disagreements with the Company’s operations, policies, or practices. No successor appointments, financial updates, or additional corporate actions were included in the report.
President & CEO Timothy R. Damadian signed the filing, confirming compliance with SEC disclosure requirements. Aside from the routine leadership transition, the 8-K contains no material financial data or strategic changes.
FAQ
What is the current stock price of Fonar (FONR)?
What is the market cap of Fonar (FONR)?
What is Fonar Corp's primary area of expertise?
How does Fonar generate its revenue?
What makes Fonar's MRI scanners unique?
Who are the primary customers of Fonar Corp?
What role does innovation play at Fonar Corp?
How is Fonar positioned in the competitive medical equipment industry?
